Develops human-like enzyme therapeutics for cancer, focusing on safety, reduced off-target activity, and in vivo stability. Leads preclinical-to-IND translation, biomarker-guided patient selection, and rational combinations across hematologic malignancies and solid tumors for safer, durable responses.